Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Peripheral Arterial Disease Therapeutics Market Pipeline Review, H2 2016

Wednesday, November 30, 2016 3:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Peripheral Arterial Disease Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics.

Peripheral Arterial Disease therapeutics industry report provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Arterial Disease and features dormant and discontinued projects.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won’t heal, slower growth of toenails and erectile dysfunction in men.

Browse more detail information about Peripheral Arterial Disease market report at: http://www.absolutereports.com/peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-pipeline-review-h2-2016-10435013

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Peripheral Arterial Disease – Pipeline Review, H2 2016:

  • AnGes MG, Inc.
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Athersys, Inc.
  • Bayer AG
  • Betagenon AB
  • BiogenCell Ltd.
  • CardioVascular BioTherapeutics, Inc.
  • Celgene Corporation
  • Diffusion Pharmaceuticals Inc
  • Hemostemix Ltd
  • ID Pharma Co., Ltd.

And Others

Get a PDF Sample of Peripheral Arterial Disease Market Research Report at: http://www.absolutereports.com/enquiry/request-sample/10435013

Drug Profiles of Included in Peripheral Arterial Disease Therapeutics Development Market Report

  • ACP-01
  • AEM-28
  • ALD-301
  • Annexin A-5
     

Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10435013

Key Topics Covered:
1.Introduction
2.Peripheral Arterial Disease Overview
3.Peripheral Arterial Disease Therapeutics Development
4.Pipeline Products for Peripheral Arterial Disease – Overview
5.Pipeline Products for Peripheral Arterial Disease – Comparative Analysis
6.Peripheral Arterial Disease – Therapeutics under Development by Companies
7.Peripheral Arterial Disease – Therapeutics under Investigation by Universities/Institutes
8.Peripheral Arterial Disease Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Peripheral Arterial Disease – Products under Development by Companies
13.Peripheral Arterial Disease – Products under Investigation by Universities/Institutes
14.Peripheral Arterial Disease – Companies Involved in Therapeutics Development
15.Peripheral Arterial Disease Drug Profiles
16.Peripheral Arterial Disease Dormant Projects
17.Peripheral Arterial Disease Discontinued Products
18.Peripheral Arterial Disease Featured News & Press Releases

Featured News & Press Releases

Oct 25, 2016: Proteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference

Oct 20, 2016: Dr. Jackie R. See M.D. Joins AngioSoma, Scientific Advisory Board

Oct 20, 2016: Proteon Therapeutics Appoints Paul Hastings Chairman of Its Board of Directors

Oct 11, 2016: AngioSoma Files 3 New Patent Applications on Liprostin

Oct 03, 2016: Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada

Sep 29, 2016: Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients

Sep 28, 2016: Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS

Aug 11, 2016: Athera Biotechnologies completes First-in-Patient Study with New Antibody Against Immunovascular Disease

May 24, 2016: Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association – European Dialysis & Transplant Association Congress (ERA-EDTA)

Apr 13, 2016: Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease

Feb 04, 2016: Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery Disease

Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015

Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor

Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics’ PRT-201 in Peripheral Artery
And Continue…

Get Discount on Peripheral Arterial Disease Market Research Report at: http://www.absolutereports.com/enquiry/request-discount/10435013

List of Tables

  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2016 11
  • Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Comparative Analysis, H2 2016 12
  • Number of Products under Development by Companies, H2 2016 13
  • Number of Products under Development by Companies, H2 2016 (Contd..1) 14
  • Comparative Analysis by Late Stage Development, H2 2016 15
  • Comparative Analysis by Clinical Stage Development, H2 2016 16
  • Comparative Analysis by Early Stage Development, H2 2016 17
  • Comparative Analysis by Unknown Stage Development, H2 2016 18
  • Products under Development by Companies, H2 2016 19

 

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2 2016

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016 

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.